UNSPSC 51284711: Midecamycin acetate

This classification denotes a leucomycin and macrolides with the molecular formula C45H71NO17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3T48CPS7U2, chemically known as leucomycin v, 3b,9-diacetate 3,4b-dipropanoate, but more generally known as midecamycin acetate, which bears US NIH Compound Identifier 5282188. European Medicines Agency schedules midecamycin acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08951MIG.

Most nations, for tariff purposes, schedule midecamycin acetate under HS 29419000. SMILES: CCC(=O)O[C@@H]1CC(=O)O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)OC(=O)C)N(C)C)O)CC=O)C)OC(=O)C)C.

UNSPSC 51284711 Midecamycin acetate is a Commodity code nominally identifying a specific macrolide antibiotic, but recent state and local opportunities do not reflect procurement activity under this code's actual scope. The four most recent opportunities posted under this code designation cover naloxone and drug deactivation systems, therapeutic pharmacy initiative direct-to-manufacturer prescriptions, emergency medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing — none of which involve midecamycin acetate or related macrolide products. The mismatch between the code's nominal pharmaceutical classification and the actual procurements suggests either miscoding in state and local procurement systems or that this UNSPSC category does not reflect current demand patterns in state and local markets.

The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating states including Oregon). Geographic activity includes Florida, Texas, Minnesota, and Oregon. Because the code shows no relevant recent activity aligned with midecamycin acetate or related macrolide antibiotics, business development professionals should confirm whether procurement under this code is active in target jurisdictions before investing pursuit resources. The opportunities cited above indicate that state and local pharmaceutical procurement is concentrated in broad generic-drug cooperative agreements, emergency medical supplies for first responders, and specialty direct-to-manufacturer programs — categories that do not map to single-entity antibiotic procurement.